Kenn Samala· @KSamalaMD · X·· 21 小时前评分70
正文 · 机器翻译
NSCLC 中 ctDNA 靶向治疗的有趣整合
✅️ 基线 ctDNA 不可检测 → 预后良好，可能可以考虑 Osimertinib 单药治疗
✅️ 如果在 3-4 周后仍未实现 ctDNA 清除 → 在 osi 单药治疗基础上加用化疗可获得更长的中位 PFS
#ESMO26
18 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
2719RO按 Rapid oral 1: NSCLC, metastatic 对上
FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)
https://esmocongress.esmo.orgLBA73按 Rapid oral 1: NSCLC, metastatic 对上
PACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line
https://esmocongress.esmo.org来源：Kenn Samala · x.com